What diseases does larotrectinib specifically target?

Larotrectinib is a highly selective TRK inhibitor specifically designed to treat locally advanced or metastatic solid tumors caused by NTRK gene fusions, regardless of the location of the tumor. Its innovation lies in targeting the genetic properties (gene fusion) of the tumor rather than its anatomical location, providing treatment options for patients with a variety of solid tumors.

Indications

Larotrectinib is suitable for the following diseases or tumor types, which are closely related toNTRK gene fusion:

1.Soft tissue sarcoma: such as fibrosarcoma, especially infantile fibrosarcoma in pediatric patients, responds significantly to larotrectinib.

2.Thyroid cancer: Some patients with differentiated or anaplastic thyroid cancer have NTRK fusion and may benefit from larotrectinib treatment.

3.Lung cancer: AlthoughNTRK fusion is less common in lung cancer, larotrectinib is an effective option for patients who carry mutations in this gene.

4.Salivary gland cancer: especially the rare secretory salivary gland cancer (secretory carcinoma).

5.Gastrointestinal tumors: including gastric cancer, colorectal cancer, etc. Patients with NTRK fusion can be treated with larotrectinib.

6.Brain tumors: Central nervous system tumors such as gliomas may also carryNTRK gene fusions.

Based on clinical trials (NAVIGATE, SCOUT and LOXO-TRK-14001), larotrectinib showed significant efficacy in multiple tumor types: overall objective response rate (ORR) reached 75%, of which 22% was complete response (CR). This shows that larotrectinib has a strong inhibitory effect on a variety of NTRK fusion-positive solid tumors.

Larotinib breaks through the traditional treatment model based on tumor location and is suitable for any solid tumor patient carryingNTRK gene fusion, regardless of age, lesion location or cancer type.

Larotinib is mainly used to treat advanced solid tumors caused byNTRK gene fusion. Although the incidence of gene fusion is low (accounting for less than 1% of all tumors), in specific tumors, such as fibrosarcoma, salivary gland cancer, etc., the proportion of NTRK fusion is higher. Larotrectinib provides a precise treatment plan for such patients.

xa0

Reference materials:

1.Bayerofficial website,https://www.bayer.com

2.U.S. Food and Drug Administration (FDA), https://www.fda.gov

3.New England Journal of Medicine,https://www.nejm.org